Tag: trial
Harnessing a Pioneering Cell Therapy Treatment for COVID-19 Patients with ARF
A world-leading UK-wide trial supported by NIHR is offering a pioneering cell therapy treatment for patients with acute respiratory failure (ARF) caused by COVID-19. The groundbreaking study, led by experts at Queen's... read more
Adjuvant therapeutic plasma exchange in septic shock
The hallmark of sepsis is a pathological host response to an infection that may lead to organ dysfunction, shock and high mortality. Besides numerous circulating mediators initiating inflammation, vascular barrier breakdown... read more
Effect of Out-of-Hospital Sodium Nitrite on Survival to Hospital Admission After Cardiac Arrest
Among patients with out-of-hospital cardiac arrest, administration of sodium nitrite, compared with placebo, did not significantly improve survival to hospital admission. These findings do not support the use of sodium nitrite... read more
COVID-19 Blood Plasma Trial Finds No Benefit in Severely Ill Patients
An international trial testing convalescent blood plasma on COVID-19 patients with moderate and severe illness has halted enrolment of severely ill COVID-19 patients requiring intensive care after it found no benefit. The... read more
Mortality Among LVAD Recipients Ineligible for Clinical Trials
These findings suggest that while treatment for patients who are ineligible for left ventricular assist device (LVAD) trial inclusion should be weighed against medical management, more consideration could be given to designing... read more
Cost-effectiveness of Adrenaline for Out-of-Hospital Cardiac Arrest
Adrenaline was not cost-effective when only directly related costs and consequences are considered. However, incorporating the indirect economic effects associated with transplanted organs substantially alters cost-effectiveness,... read more
Allergic Reactions to COVID-19 Vaccine
To date, the development of mRNA vaccines for the prevention of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a success story, with no serious concerns identified in the ongoing... read more
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
The mRNA-1273 vaccine showed 94.1% efficacy at preventing COVID-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. The trial enrolled 30,420 volunteers... read more
The Evolving Armamentarium of COVID-19 Therapeutics
Multiple repositories have been created for the vast scientific outpouring of COVID-19 research. The NIH regularly updates its treatment guidelines, which will be the primary reference for this review. To cut to the... read more
Pfizer and BioNTech Speed Up Timeline for COVID-19 Vaccine
Pfizer and its partner BioNTech plan to offer their Covid-19 vaccine to any clinical trial volunteer who received placebo by March 1, several months earlier than initially planned. The decision represents the conclusion... read more
Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19
Primary outcome in the RECOVERY trial and in the WHO REACT meta-analysis was 28-day mortality. Assessing 28-day mortality may not be the optimal outcome in a trial. Since patients with severe COVID-19 often require prolonged... read more
External Corroboration That Corticosteroids May Be Harmful to Septic Shock Endotype A Patients
This exploratory analysis provides further evidence that corticosteroid exposure may be associated with increased mortality among septic shock endotype A patients. We previously reported gene expression-based endotypes... read more
The hospital of the future – building intelligent environments to facilitate safe and effective acute care delivery
Both the integrity of the healing professions and the safety of our patients hinge on our ability to identify and overcome barriers to effective, error-free care delivery. These barriers are not due to the lack of a sophisticated... read more
Harmonizing Heterogeneous Endpoints in COVID-19 Trials Without Loss of Information
All ongoing clinical trials should include a stacked probability plot in their statistical analysis plan as descriptive analysis. While primary analysis should be on an early endpoint with appropriate capability to be... read more
NIH ACTIV trial of blood thinners pauses enrollment of critically ill COVID-19 patients
Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients. Among critically ill COVID-19... read more
Weaning the patient: between protocols and physiology
Ventilator weaning forms an integral part in critical care medicine and strategies to shorten duration are rapidly evolving alongside our knowledge of the relevant physiological processes. The purpose of the current review... read more
Oral Vitamin K Lowers the International Normalized Ratio More Rapidly
Oral vitamin K lowers INR more rapidly than subcutaneous vitamin K in asymptomatic patients who have supratherapeutic INR values while receiving warfarin. Warfarin therapy was withheld, and 1 mg of vitamin K was given... read more
Genetic Mechanisms of Critical Illness in COVID-19
Host-mediated lung inflammation is present, and drives mortality, in critical illness caused by COVID-19. Host genetic variants associated with critical illness may identify mechanistic targets for therapeutic development. Here... read more
Improved Oxygenation After Prone Positioning May Be a Predictor of Survival in Patients With ARDS
We found a significant difference in the Pao2:Fio2 ratio after the first prone positioning between ICU survivors and nonsurvivors. The improvement in oxygenation after the first prone positioning was a significant predictor... read more
Myorelaxants in ARDS patients
Neuromuscular blocking agents (NMBAs) inhibit patient-initiated active breath and the risk of high tidal volumes and consequent high transpulmonary pressure swings, and minimize patient/ ventilator asynchrony in acute respiratory... read more
Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion of People With HIV in Anti–PD1/PDL1 Trials
This study identified encouraging trends in the inclusion of PLWH in anti–PD1/PDL1 cancer trials that occurred in the period following the initiation of CTEP advocacy. Work is needed to examine what impact this will have... read more
Will COVID-19 Vaccines Save Lives? Current Trials Aren’t Designed To Tell Us
The world has bet the farm on vaccines as the solution to the pandemic, but the trials are not focused on answering the questions many might assume they are. As phase III trials of covid-19 vaccines reach their target... read more
